Bridget A Oppong1, Angel A Rolle2, Amara Ndumele3, Yaming Li4, James L Fisher5, Oindrila Bhattacharyya5, Toyin Adeyanju6, Electra D Paskett6. 1. Department of Surgery, The Ohio State University College of Medicine, Columbus, OH, USA. bridget.oppong@osumc.edu. 2. Central State University, Wilberforce, OH, USA. 3. Wexner College of Medicine, The Ohio State University, Columbus, OH, USA. 4. Department of Surgery, The Ohio State University College of Medicine, Columbus, OH, USA. 5. James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, OH, USA. 6. Department of Medicine, and Comprehensive Cancer Center, Ohio State University, Columbus, OH, USA.
Abstract
PURPOSE: Black women have higher breast cancer mortality rates than other groups, with Triple-negative breast cancer (TNBC) being more common among AAs with a worse prognosis. Our study seeks to explore differences among Non-Hispanic Black (NHB) vs. White (NHW) women, with Stage IV TNBC, focusing on survival and treatment patterns. METHODS: SEER database was queried for TNBC patients diagnosed with metastatic disease from 2012 to 2016. Neighborhood socioeconomic status (nSES) was defined using the Yost index based on income, education, housing, and employment. Univariate and multivariate analyses were performed to evaluate receipt of surgery, radiation, and chemotherapy. Overall survival was evaluated using Kaplan-Meier curve and Cox proportional hazards model analysis. RESULTS: 25,761 TNBC cases were identified with 1420 being metastatic (5.5%). Bone was the most common site for metastasis, with patients' age being 63.7 years for NHW vs. 59.5 years for NHB. NHB women had the highest percentage of low nSES (62.3% vs 29.3%; p value = 0.001). On univariate analysis, fewer NHBs received radiation compared to NHWs (27.1 vs. 32.6%; p value = 0.040). On multivariate analysis, all women were less likely to undergo treatment if unmarried (p value < 0.01). NHB women had lower median survival compared to NHW women (13 vs. 15 months; p value < 0.01). Receipt of surgery and chemotherapy reduced the risk of mortality (p value < 0.01). CONCLUSION: NHB women had lower median survival with metastatic TNBC. Race was associated with different treatment utilization. With a mortality differential between NHW and NHB women with metastatic TNBC, more investigation is needed to inform strategies to reduce this disparity.
PURPOSE: Black women have higher breast cancer mortality rates than other groups, with Triple-negative breast cancer (TNBC) being more common among AAs with a worse prognosis. Our study seeks to explore differences among Non-Hispanic Black (NHB) vs. White (NHW) women, with Stage IV TNBC, focusing on survival and treatment patterns. METHODS: SEER database was queried for TNBC patients diagnosed with metastatic disease from 2012 to 2016. Neighborhood socioeconomic status (nSES) was defined using the Yost index based on income, education, housing, and employment. Univariate and multivariate analyses were performed to evaluate receipt of surgery, radiation, and chemotherapy. Overall survival was evaluated using Kaplan-Meier curve and Cox proportional hazards model analysis. RESULTS: 25,761 TNBC cases were identified with 1420 being metastatic (5.5%). Bone was the most common site for metastasis, with patients' age being 63.7 years for NHW vs. 59.5 years for NHB. NHB women had the highest percentage of low nSES (62.3% vs 29.3%; p value = 0.001). On univariate analysis, fewer NHBs received radiation compared to NHWs (27.1 vs. 32.6%; p value = 0.040). On multivariate analysis, all women were less likely to undergo treatment if unmarried (p value < 0.01). NHB women had lower median survival compared to NHW women (13 vs. 15 months; p value < 0.01). Receipt of surgery and chemotherapy reduced the risk of mortality (p value < 0.01). CONCLUSION: NHB women had lower median survival with metastatic TNBC. Race was associated with different treatment utilization. With a mortality differential between NHW and NHB women with metastatic TNBC, more investigation is needed to inform strategies to reduce this disparity.
Authors: Joseph Lipscomb; Theresa W Gillespie; Michael Goodman; Lisa C Richardson; Lori A Pollack; A Blythe Ryerson; Kevin C Ward Journal: Breast Cancer Res Treat Date: 2012-01-26 Impact factor: 4.872
Authors: Lisa A Carey; Charles M Perou; Chad A Livasy; Lynn G Dressler; David Cowan; Kathleen Conway; Gamze Karaca; Melissa A Troester; Chiu Kit Tse; Sharon Edmiston; Sandra L Deming; Joseph Geradts; Maggie C U Cheang; Torsten O Nielsen; Patricia G Moorman; H Shelton Earp; Robert C Millikan Journal: JAMA Date: 2006-06-07 Impact factor: 56.272
Authors: Curtis J Wray; Uma R Phatak; Emily K Robinson; Rebecca L Wiatek; Alyssa G Rieber; Anneliese Gonzalez; Tien C Ko; Lillian S Kao Journal: Ann Surg Oncol Date: 2013-02-24 Impact factor: 5.344
Authors: Cletus A Arciero; Jing Yang; Limin Peng; Kevin C Ward; Ruth O'Regan; Aysegul A Sahin; Xiaoxian Li Journal: Breast Cancer Res Treat Date: 2017-08-30 Impact factor: 4.872
Authors: Shaheenah Dawood; Kristine Broglio; Ana M Gonzalez-Angulo; Aman U Buzdar; Gabriel N Hortobagyi; Sharon H Giordano Journal: J Clin Oncol Date: 2008-08-25 Impact factor: 44.544